ไทย
日本語
In the context of an FUE (Follicular Unit Excision) hair transplant, exosome injection is a regenerative medicine technique used to enhance surgical outcomes by leveraging the body’s natural cellular communication system.
Rationale
Exosomes are nanosized vesicles secreted by stem cells (often Mesenchymal Stem Cells or MSCs) that act as “biological messengers”. They carry a concentrated cargo of growth factors, cytokines, and microRNA.
The rationale for using them during FUE is to provide a “supercharged” support system for hair follicles during their most vulnerable stage—when they are temporarily disconnected from their blood supply during the transfer process.
Key Benefits
Improved Graft Survival:
Exosomes can be used as a “holding solution” for harvested follicles, keeping them viable for 36 to 96 hours outside the body. This reduces graft loss rates.
Accelerated Healing:
Their anti-inflammatory properties significantly reduce post-operative redness, swelling, and pain in both the donor and recipient areas.
Faster Hair Growth:
By activating the Wnt/β-catenin pathway, exosomes encourage transplanted follicles to enter the active growth (anagen) phase more quickly, often showing visible results as early as 2.3 months compared to 3.7 months in standard care.
Reduced “Shock Loss”:
Exosome signaling helps prevent newly transplanted follicles from entering a dormant (telogen) stage too quickly, minimizing temporary shedding.
Enhanced Density & Quality:
They stimulate existing miniaturized hair around the transplant site, leading to a fuller overall appearance and thicker hair shaft diameter (up to 31.6% increase in some studies).
Comparison: Exosomes vs. PRP
While both are popular adjuncts, exosomes are generally considered more potent than Platelet-Rich Plasma (PRP).
Feature Exosome. PRP
Origin Lab-purified stem cell. Patient’s own blood
Potency 1,000+ growth factors. ~7-25 growth factors
Sessions Usually 1–2 sessions. Typically 3–6 sessions
Response Faster ( 4 weeks). Gradual (2–6 months)
At 34th ISHRS World Congress meeting.
Exosome-Enriched Preservation Solution Enhances Follicular Survival in Hair Restoration Surgery: A Prospective Comparative Study of 100 Patients with Androgenetic Alopecia (GS-039)
Friday, October 16, 2026
10:53 AM – 10:58 AM
Room: Asia 2 & 3
Laura M. Caicedo, MD, FISHRS: No financial relationships to disclose
Abstract: Introduction
Exosomes are lipid bilayer nanovesicles (30-150 nm) derived from bovine colostrum stem cells that mediate intercellular communication and contain high concentrations of growth factors. Recent evidence suggests that exosome therapy promotes hair follicle regeneration and neogenesis in androgenetic alopecia. However, their role as a graft preservation medium during follicular unit extraction (FUE) hair transplantation remains unexplored. We hypothesized that incorporating exosomes into the preservation solution could enhance follicular unit survival and increase post-transplant density.
Objective
To evaluate follicular survival and density in the recipient area when an exosome-enriched preservation solution is used during FUE hair transplantation in patients with androgenetic alopecia, compared with standard Ringer Lactate and HypoThermosol (RL+HT).
Materials and Methods
A prospective, split-scalp, case-control study was conducted on 100 male patients (aged 30-50) with androgenetic alopecia (Hamilton-Norwood III-V), stabilized with medical therapy for at least six months. All procedures were performed as long-hair FUE by a single surgeon under standardized conditions (19°C). Per patient, 250 follicular units (1-2 hairs) were preserved in an exosome-enriched solution (5 ml exosomes diluted 1.25/5 ml in RL+HT, 20 ml total) and 250 in standard RL+HT (10 ml), all maintained at 4°C until implantation. The scalp was divided along the median line: the right hemiforehead received exosome-preserved grafts (case) and the left received RL+HT grafts (control). Four standardized trichoscopic points-two per hemiforehead-were assessed preoperatively and at 2.5, 5, and 12 months using Trichoscan (FotoFinder, Trichoscale DX). Parameters measured included hair count, follicular density (hairs/cm²), terminal-to-vellus ratio, mean shaft thickness, and hairs per follicular unit. Biopsy specimens from each solution were submitted for histopathological analysis.
Results
Trichoscopic follow-up demonstrated improvement in both groups; however, exosome-preserved areas consistently outperformed controls. Follicular density showed a substantially greater increase in the exosome group compared with RL+HT. Total hair count exhibited a markedly higher increase in the case area, with the exosome group demonstrating approximately three-fold greater improvement. Terminal hair count rose significantly in exosome-treated zones, with more than a seven-fold difference in percentage increase relative to controls. Hairs per follicular unit also favored the exosome group, showing approximately twice the improvement of controls. Mean shaft thickness did not differ significantly between groups. Postoperative spray washes with the exosome solution were administered to the case area, potentially contributing to enhanced healing.
Conclusions
The addition of exosomes to the graft preservation solution appears to enhance follicular survival following FUE transplantation in androgenetic alopecia, yielding higher density, increased total and terminal hair counts, and more hairs per follicular unit compared with standard RL+HT. No significant effect on shaft caliber was observed. Long-term 12-month follow-up is ongoing to validate these findings and assess the durability of the exosome-mediated benefit.
Take Home Message: The addition of exosomes to the graft preservation solution appears to enhance follicular survival following FUE transplantation in androgenetic alopecia, yielding higher density, increased total and terminal hair counts, and more hairs per follicular unit compared with standard RL+HT. No significant effect on shaft caliber was observed. Long-term 12-month follow-up is ongoing to validate these findings and assess the durability of the exosome-mediated benefit.
